Objective: To evaluate the efficacy of two mostly used intravesical agent, BCG and mitomycin c, in case of tumor recurrence. Method: Between 2002 and 2008, we performed TUR-BT to 127 patients whom pathology results were superficial bladder cancer. 41 patients were treated with intravesical BCG once for week 6 weeks then monthly up to one year beginning from 14. day postoperatively. 26 patients were treated with intravesical mitomycin c, beginning from first 6 h postoperatively and once a week for 8 weeks. 60 patients didn't get any further treatment, and excluded from study. Results: For BCG group, expected disease free interval was 58.1 months, and 34.6 months for mitomycin c group. When two groups compared for expected disease free interval, statistically significant difference observed (p=0.017). For BCG and mitomycin c group, recurrence was seen in 13 and 9 patients, respectively. For patients treated with BCG, 1 and 3 years disease free survival rate was %92.7 and %75.7, respectively. In mitomycin c group 1 and 3 years disease free survival rate was %76.9 and %62.9. Conclusion: Intravesical adjuvant BCG maintenance therapy is more effective for tumor reccurence than intravesical mitomycin c therapy.